Laxxon Medical Announces Positive Pilot PK Study Results for Advanced Levodopa/Carbidopa Asset for Parkinson’s Disease, LMX.5 Laxxon Medical Tue, Feb 4, 2025, 9:00 AM 3 min read ...
The LXM.5 pilot study reveals an 80% bioavailability increase compared to competing products combining levodopa and carbidopa. The study additionally shows sustained and smooth levodopa levels in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback